Urology Diagnostics - About the company
Urology Diagnostics is a deadpooled company based in San Francisco (United States), founded in 2015 by Carly King. It operates as a Genomic diagnostics company transforming urologic cancer care through innovative technology. Urology Diagnostics has raised an undisclosed amount in funding from Illumina. The company has 159 active competitors, including 54 funded and 38 that have exited. Its top competitors include companies like Guardant Health, GRAIL and BillionToOne.
Company Details
Genomic diagnostics company transforming urologic cancer care through innovative technology. They simplify and accelerate cancer diagnostics, providing clinicians and patients with personalized data and actionable insights. Leveraging liquid biopsy and next-generation sequencing, they extract DNA from urine to detect cancer risks earlier. Their non-invasive genomic urine test reveals cancer with accuracy, changing the timeline for recurrence detection. The company is dedicated to advancing cancer care and improving outcomes through reliable detection, monitoring, and prediction of urothelial cancer risk. They utilize machine learning to personalize cancer care and identify recurrences sooner. Their services include genomic data analysis, clinical program strategy, and medical affairs. They are committed to quality control, data validation, and patient information protection.
- Website
- urologydx.com
- Social
- Email ID
- *****@urologydx.com
Key Metrics
Founded Year
2015
Location
San Francisco, United States
Stage
Deadpooled
Latest Funding Round
Investors
Ranked
173rd among 202 competitors
Similar Companies
Sign up to download Urology Diagnostics' company profile
Urology Diagnostics's funding and investors
Urology Diagnostics has raised funding over 1 round. Its latest funding round was a Seed round on Aug 06, 2015 for $*****. 1 investor participated in its latest round. Urology Diagnostics has 1 institutional investor.
Here is the list of recent funding rounds of Urology Diagnostics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 06, 2015 | 4122515 | Seed | 9562662 | 4562937 | 6181788 | 9852426 |
Access funding benchmarks and valuations. Sign up today!View details of Urology Diagnostics's funding rounds and investors
Urology Diagnostics' founders and board of directors
Founder? Claim ProfileThe founders of Urology Diagnostics is Carly King.
Here are the details of Urology Diagnostics' key team members:
- Carly King: Co-Founder of Urology Diagnostics.
- Trevor Levin: CEO of Urology Diagnostics.
View details of Urology Diagnostics's Founder profiles and Board Members
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Urology Diagnostics's Competitors and alternates
Top competitors of Urology Diagnostics include Guardant Health, GRAIL and BillionToOne. Here is the list of Top 10 competitors of Urology Diagnostics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Guardant Health 2012, Redwood City (United States), Public | Developer of digital sequencing technology for cancer detection | $557M | 79/100 | |
2nd |  GRAIL 2016, Menlo Park (United States), Public | Developer of a screening platform for circulating tumor DNA to detect cancer | $2B | 69/100 | |
3rd | BillionToOne 2015, San Francisco (United States), Public | Provider of cell-free cancer liquid biopsy test | $389M | 69/100 | |
4th |  Foresight Diagnostics 2020, Aurora (United States), Acquired | Developer of minimally-invasive liquid biopsy test for the detection of cancer | $104M | 66/100 | |
5th | Scipher Medicine 2014, Waltham (United States), Series D | Provider of precision medicine based on liquid biopsy test | $233M | 65/100 | |
6th | Saga Diagnostics 2016, Morrisville (United States), Acquired | Provider of tests for detection and analysis of circulating tumor DNA | $17.9M | 64/100 | |
7th | Delfi Diagnostics 2019, Baltimore (United States), Series B | Provider of DNA sequencing for cancer detection | $332M | 64/100 | |
8th | Developer of cancer diagnostic tests | - | 61/100 | ||
9th | _1559800772180.png?devicePixelRatio=2&height=30&width=30){kind=logo} Naveris 2017, Waltham (United States), Acquired | Provider of blood tests for early cancer detection | $68.5M | 60/100 | |
10th | Codiak BioSciences 2015, Cambridge (United States), Public | Developer of exosome-based drugs and diagnostics for cancer treatment | $168M | 57/100 | |
173rd | Urology Diagnostics 2015, San Francisco (United States), Deadpooled | Genomic diagnostics company transforming urologic cancer care through innovative technology | - | 16/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Urology Diagnostics's competitors? Click here to see the top ones
Urology Diagnostics's Investments and acquisitions
Urology Diagnostics has made no investments or acquisitions yet.
Reports related to Urology Diagnostics
Here is the latest report on Urology Diagnostics's sector:
News related to Urology Diagnostics
•
Illumina Welcomes New Startups To Its Accelerator ProgramBio-IT World•Aug 06, 2015•Urology Diagnostics
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Urology Diagnostics
Explore our recently published companies
- Viet Tiles - Ho Chi Minh City based, Unfunded company
- Mile Twenty Six - 2002 founded, Unfunded company
- VousVous - 2026 founded, Unfunded company
- 7X Weddings - Ahmedabad based, Unfunded company
- Fabcart - Unfunded company
- Zearch - United Kingdom based, 2019 founded, Unfunded company
